CD8 + T EM , CD4 + T EM and T reg subsets in the pretreatment (day 4, left) and posttreatment (day +12, right) samples were analyzed for (top to bottom): T cell-bound nivolumab (detected with anti-IgG4-PE), residual unoccupied PD-1 (direct PD-1 detection with anti-PD-1 (CD279) BV421), activation markers (MHC class II, OX40) and GzmB. Immune checkpoint (LAG3, CTLA-4, TIGIT) expression analysis was performed on pretreatment (day 9) samples. The numbers indicate the percentage of cells in the respective gates.
